最新动态
8月20日 - ** 制药公司莫德纳（Moderna） MRNA.O 和默克（Merck） MRK.N 的股价在盘前 交易中分别下跌逾8%至160.3美元，和1.3%至150.3美元
**两家公司周三表示，在一项晚期临床试验中，Moderna的个性化mRNA癌症疫苗 (link) 与默克的免疫疗法“Keytruda”联合使用，降低了黑色素瘤复发和扩散的风险，这是癌症治疗新领域的一项重大突破
** 周三，Moderna股价翻了一番多，其市值因此增加了440多亿美元
** “尽管我们对市场对治疗性癌症疫苗‘intismeran autogene’取得决定性成功作出的积极反应感到欣喜，但这种反应过于乐观，并产生了我们认为难以满足的预期，”Leerink Partners的分析师表示
** 截至前一交易日收盘，MRNA股价年内累计涨幅已达491%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.